PharmaEssentia and FORUS Therapeutics Partner to Commercialize BESREMi

PharmaEssentia Corporation, a biopharmaceutical company from Taiwan, using expertise and scientific principles, will distribute BESREMi in Canada for treating polycythemia vera through an exclusive licensing agreement with FORUS Therapeutics Inc.

FORUS specializes in the Canadian hematology and oncology market, boasting substantial expertise in local drug registration and commercialization. According to the agreement, biopharmaceutical firm is granting FORUS in Canada a license for BESREMi for PV, with the possibility of extending to other MPN indications later on.

FORUS will be responsible for managing the drug registration and commercialization of BESREMi in Canada, with the chance to receive milestone payments totaling $107 million USD for achieving approval of BESREMi in PV and meeting sales goals. FORUS plans to make some milestone payments by 2024 and provide PharmaEssentia with royalties in the double-digit percentage on sales.

“FORUS and PharmaEssentia are aligned in our missions to bring new treatments to patients with hematologic and oncologic conditions that may meaningfully enhance their lives,” said Ko-Chung Lin, Ph.D., Founder and CEO of PharmaEssentia. “We continue to expand scientific data to demonstrate the clinical value of BESREMi for patients with MPNs such as PV, and we look forward to collaborating with FORUS to introduce BESREMi in Canada, to expand our footprint in North America and to benefit even more patients with PV.”